Effect of histone deacetylase inhibitors on HIV production in latently infected, resting CD4(+) T cells from infected individuals receiving effective antiretroviral therapy
- PMID: 22732922
- PMCID: PMC3491743
- DOI: 10.1093/infdis/jis412
Effect of histone deacetylase inhibitors on HIV production in latently infected, resting CD4(+) T cells from infected individuals receiving effective antiretroviral therapy
Abstract
Persistence of the latent viral reservoir has been recognized as a major obstacle to eradicating human immunodeficiency virus (HIV) in infected individuals receiving antiretroviral therapy. It has been suggested that histone deacetylase inhibitors (HDACis) may purge HIV in the latent viral reservoir. However, the effect of HDACis on the degree and extent of HIV expression in the latent viral reservoir has not been fully delineated. Here we demonstrate that HDACis do not induce HIV production in the latent viral reservoir of aviremic individuals. Therefore, alternative therapeutic strategies may be necessary to eliminate HIV in the latent viral reservoir.
Figures

Similar articles
-
In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV infection.Retrovirology. 2016 May 21;13(1):36. doi: 10.1186/s12977-016-0268-7. Retrovirology. 2016. PMID: 27206407 Free PMC article.
-
In Vitro Reactivation of Replication-Competent and Infectious HIV-1 by Histone Deacetylase Inhibitors.J Virol. 2015 Dec 9;90(4):1858-71. doi: 10.1128/JVI.02359-15. Print 2016 Feb 15. J Virol. 2015. PMID: 26656693 Free PMC article.
-
Innate Immune Activity Correlates with CD4 T Cell-Associated HIV-1 DNA Decline during Latency-Reversing Treatment with Panobinostat.J Virol. 2015 Oct;89(20):10176-89. doi: 10.1128/JVI.01484-15. Epub 2015 Jul 29. J Virol. 2015. PMID: 26223643 Free PMC article. Clinical Trial.
-
Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy.Annu Rev Immunol. 2000;18:665-708. doi: 10.1146/annurev.immunol.18.1.665. Annu Rev Immunol. 2000. PMID: 10837072 Review.
-
Therapeutic Approaches to Eradicate Latent HIV-1 in Resting CD4+ T Cells.Curr Top Med Chem. 2016;16(10):1191-7. doi: 10.2174/1568026615666150901114138. Curr Top Med Chem. 2016. PMID: 26324046 Review.
Cited by
-
Eliminating the latent HIV reservoir by reactivation strategies: advancing to clinical trials.Hum Vaccin Immunother. 2013 Apr;9(4):790-9. doi: 10.4161/hv.23202. Epub 2013 Apr 1. Hum Vaccin Immunother. 2013. PMID: 23563519 Free PMC article. Review.
-
Quantification of HIV-1 latency reversal in resting CD4+ T cells from patients on suppressive antiretroviral therapy.Proc Natl Acad Sci U S A. 2014 May 13;111(19):7078-83. doi: 10.1073/pnas.1402873111. Epub 2014 Mar 31. Proc Natl Acad Sci U S A. 2014. PMID: 24706775 Free PMC article.
-
Transcriptional Reprogramming during Effector-to-Memory Transition Renders CD4+ T Cells Permissive for Latent HIV-1 Infection.Immunity. 2017 Oct 17;47(4):766-775.e3. doi: 10.1016/j.immuni.2017.09.014. Immunity. 2017. PMID: 29045905 Free PMC article.
-
Development of 5' LTR DNA methylation of latent HIV-1 provirus in cell line models and in long-term-infected individuals.Clin Epigenetics. 2016 Feb 19;8:19. doi: 10.1186/s13148-016-0185-6. eCollection 2016. Clin Epigenetics. 2016. PMID: 26900410 Free PMC article.
-
Low Inducibility of Latent Human Immunodeficiency Virus Type 1 Proviruses as a Major Barrier to Cure.J Infect Dis. 2021 Feb 15;223(12 Suppl 2):13-21. doi: 10.1093/infdis/jiaa649. J Infect Dis. 2021. PMID: 33586775 Free PMC article. Review.
References
-
- Walensky RP, Paltiel AD, Losina E, et al. The survival benefits of AIDS treatment in the United States. J Infect Dis. 2006;194:11–9. - PubMed
-
- Richman DD, Margolis DM, Delaney M, Greene WC, Hazuda D, Pomerantz RJ. The challenge of finding a cure for HIV infection. Science. 2009;323:1304–7. - PubMed
-
- Chun TW, Engel D, Mizell SB, et al. Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1–infected patients receiving highly active antiretroviral therapy. Nat Med. 1999;5:651–5. - PubMed
-
- Kulkosky J, Nunnari G, Otero M, et al. Intensification and stimulation therapy for human immunodeficiency virus type 1 reservoirs in infected persons receiving virally suppressive highly active antiretroviral therapy. J Infect Dis. 2002;186:1403–11. - PubMed
-
- Chun TW, Davey RT, Jr, Engel D, Lane HC, Fauci AS. Reemergence of HIV after stopping therapy. Nature. 1999;401:874–5. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials